A new medication called tozorakimab has shown encouraging results in two large clinical trials (OBERON and TITANIA) that could change how we treat chronic obstructive pulmonary disease (COPD). The studies, presented at a major respiratory conference in 2026 and published in a respected medical journal, found that this drug significantly reduces the number of flare-ups (exacerbations) in people with COPD—regardless of whether they currently smoke, have stopped smoking, or have different levels of inflammation in their blood. It also works for people with varying degrees of lung function, from mild to severe COPD. This is important because more than half of people with COPD who are on standard inhaled treatments still experience flare-ups. Severe flare-ups are particularly dangerous, as research shows only about half of people survive more than 3.5 years after having one. In these studies, tozorakimab reduced moderate and severe flare-ups by about 30% overall. For people with higher levels of inflammation in their blood (300 or more), the reduction was even greater at 43%. Even those with lower inflammation (under 150), who currently have no other biologic treatment options, saw a 23% reduction in flare-ups. The drug works differently from other COPD medications because it blocks two key inflammation pathways (IL-33 through ST2 and RAGE/EGFR), which may help reduce inflammation and mucus buildup in the lungs—two major causes of COPD worsening. In a separate analysis, tozorakimab was also shown to reduce mucus plugs in the lungs, the first biologic to demonstrate this effect in a broad COPD population. These findings suggest tozorakimab could provide a new and effective option for people with COPD who continue to have flare-ups despite using standard inhaled treatments.